SOUTH SAN FRANCISCO, Calif., July 31 PoniardPharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused ononcology, today announced that the Company will present information onplatinum resistance at the Fourth Annual Moores UCSD Cancer CenterTranslational Oncology Symposium on Friday, August 1, in San Diego.
Neela Patel, Ph.D., director of preclinical and translational medicine forPoniard Pharmaceuticals, will present on the topic of "Molecular Mechanisms ofPlatinum Resistance" at 2:30 p.m. Pacific Time. Jerry McMahon, Ph.D., chairmanand chief executive officer, will participate in the symposia's concludingpanel discussion at 3:15 p.m. Pacific Time.
"Each year, 300,000 cancer patients in the United States are treated witha platinum-based chemotherapy, and most relapse after initial treatment," saidDr. McMahon. "Therefore, intrinsic or acquired resistance to platinums is asignificant treatment issue. Picoplatin, our lead product candidate, wasdesigned to overcome platinum resistance, and we are exploring the use ofgenetic markers of platinum resistance to optimize patient treatment."
About The Rebecca and John Moores UCSD Cancer Center
The Rebecca and John Moores UCSD Cancer Center seeks to bring the finestminds in treatment and research under one roof to share the latest advances inthe oncology field, and to create a fertile atmosphere that promotesnetworking and collaboration opportunities of benefit to all participants.
Information about the Moores UCSD Cancer Center and the TranslationalOncology Symposium can be found at http://cancer.ucsd.edu/symposium/index.asp.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused onthe development and commercialization of innovative oncology products toimpact the lives of people with cancer. Picoplatin, the Company's leadplatform product candidate, is a new generation platinum therapy with animproved safety profile relative to existing platinum-based cancer therapies.Picoplatin is designed to overcome platinum resistance associated withchemotherapy in solid tumors, and is being studied in multiple cancerindications, combinations and formulations. Clinical trials of intravenouspicoplatin include a Phase 3 trial in small cell lung cancer and Phase 2trials in metastatic colorectal and hormone-refractory prostate cancers, aswell as a clinical trial of oral picoplatin in solid tumors. Picoplatin hasnot been approved by any regulatory authority for use in humans. Foradditional information please visit http://www.poniard.com.
(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of PoniardPharmaceuticals, Inc.
SOURCE Poniard Pharmaceuticals